Previous Article | Next Article 
Journal of Virology, March 2000, p. 2770-2776, Vol. 74, No. 6
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
The Kinetics of VP5 mRNA Expression Is Not Critical
for Viral Replication in Cultured Cells
Pauline T.
Lieu and
Edward K.
Wagner*
Program in Animal Virology, Department of
Molecular Biology and Biochemistry, University of California,
Irvine, California 92697
Received 15 November 1999/Accepted 21 December 1999
 |
ABSTRACT |
We generated recombinant viruses in which the kinetics of
expression of the leaky-late VP5 mRNA was altered. We then analyzed the
effect of such alterations on viral replication in cultured cells. The
VP5 promoter and leader sequences from positions
36 to +20,
containing the TATA box and an initiator element, were deleted and
replaced with a strong early (dUTPase), an equal-strength leaky-late
(VP16), or a strict-late (UL38) promoter. We found that
recombinant viruses containing the dUTPase promoter inserted in the VP5
locus expressed VP5-encoding mRNA with early kinetics, while virus with
the UL38 promoter inserted expressed such mRNA with
strict-late kinetics. Further, in spite of differences in its
functional architecture, the VP16 promoter fully substituted for the
VP5 promoter. Western blot analysis demonstrated that the amounts of
VP5 capsid protein produced by the recombinant viruses differed
somewhat; however, on complementing C32 and noncomplementing Vero
cells, such viruses replicated to titers equivalent to those of the
rescued wild-type virus controls. Multistep virus growth in mouse
embryo fibroblasts, rabbit skin cells, and Vero cells also demonstrated
equivalent replication efficiencies for both recombinant and wild-type
viruses. Further, recombinant viruses did not show any impairment in
their ability to replicate on serum-starved or quiescent human lung
fibroblasts. We conclude that the kinetics of the essential VP5 mRNA
expression is not critical for viral replication in cultured cells.
 |
INTRODUCTION |
Regulated gene expression during
productive infection of herpes simplex virus type 1 (HSV-1) has been
extensively studied and reviewed (12, 14, 16, 18, 22, 23, 33, 36, 38). Three major classes of viral transcripts are expressed in a
coordinated and sequential manner, providing proteins necessary for
viral gene expression, replication, and viral assembly. The immediate-early or
transcripts, expressed in the absence of de novo
protein synthesis, encode the major regulatory proteins of the virus
(13, 24, 32, 36). These proteins are responsible for
activating and regulating the expression of later classes of genes. A
major fraction of the early or
transcripts encode proteins involved
in viral DNA replication. As the level of genome replication approaches
its maximum, expression of early transcripts declines and both the
relative and absolute rates of late transcription increase. Late
transcripts, many of which encode proteins involved in virus
morphogenesis and maturation, have been divided into two subclasses:
leaky-late (
1) and strict-late (
2). The former class of
transcripts is expressed at appreciable levels prior to the initiation
or in the absence of genome replication, and thus, expression of
proteins encoded by them is not particularly sensitive to inhibitors of
DNA replication (2, 21, 28, 34, 35).
This general pattern of regulated gene expression is typical of
productive infection by the vast majority of DNA-containing viruses,
but the actual mechanisms by which different viruses achieve this
regulation differ. In the case of HSV, a major point of regulation is
at the level of transcription, and we have demonstrated that both the
kinetics and level of expression of a particular transcript are largely
dictated by its promoter architecture (1, 6, 9, 25, 26, 29,
38).
A general tenant in modeling patterns of viral gene regulation is that
the actual time and precise level of expression of a given transcript
are of major importance in efficient productive infection and thus are
tightly controlled. The complex pattern of regulation and the
distinctive promoter structure utilized by HSV in mediating such
regulation can be taken as presumptive evidence that this is, indeed,
the case. A measure of the importance of the exact timing of the
expression of specific viral genes should come from an assessment of
the biological consequences of altering the parameters of their expression.
Desai et al. have demonstrated that a virus unable to express the gene
encoding the major capsid protein, VP5 (UL19), does not
form capsids and fails to process newly synthesized DNA into unit-length genomes (3, 20). We were interested in
determining the consequences of altering this essential protein's
kinetics of expression with regard to viral growth and pathogenesis.
Accordingly, we have generated recombinant viruses in which a strong
early (dUTPase), an equal-strength leaky-late (VP16), or a strict-late (UL38) promoter has been substituted for the VP5 promoter
in the VP5 locus of the viral genome.
We utilized a complementing cell line expressing the VP5 capsid protein
and a VP5-null virus generated by Desai et al. as a starting point
(3, 20). As reported here, we have found that recombinant
viruses containing the various promoter insertions express chimeric
transcripts containing the cap and leader sequence of the inserted
promoter and the coding sequence of the major capsid protein with the
kinetics of the inserted promoter. Thus, the substituted promoters
retain their normal kinetics of expression. Western blot analysis
demonstrated that the amounts of VP5 capsid protein produced by the
recombinant viruses differed somewhat and were roughly correlated with
the levels of mRNA expression observed. Despite this, the recombinant
viruses replicated to titers essentially equivalent to that seen with
rescued wild-type (wt) virus controls on complementing (C32) and
noncomplementing (Vero) cells. Multistep virus growth levels in mouse
embryo fibroblasts, rabbit skin fibroblasts (RSF), and Vero cells were
equivalent for recombinant and wt viruses. Further, recombinant viruses
did not show any impairment in ability to replicate on serum-starved or
quiescent human lung fibroblasts (HLF).
From this we conclude that the kinetics of expression of a required
protein need not be tightly regulated for virus replication in a
variety of cultured cells. We are currently investigating the effects
of these viruses on pathogenesis in animals.
 |
MATERIALS AND METHODS |
Cells.
RSF, Vero cells, and mouse embryo fibroblasts were
maintained at 37°C under an atmosphere of 5% carbon dioxide in Eagle
minimum essential medium containing 5% cadet calf serum, 100 U of
penicillin per ml, and 100 µg of streptomycin per ml. C32 cells,
which complement VP5-null mutants (20), were a gift of P. Desai and S. Person. They were maintained under the conditions
described above except that 10% fetal calf serum was used. Primary HLF
(CCL-151) obtained from the American Type Culture Collection were
maintained in Ham (F12K) medium with 15% fetal calf serum (FCS) in the
absence of antibiotics.
Virus.
The VP5-null virus K5dZ was generated by partial
deletion of the VP5 coding region and insertion of a lacZ
gene as described in reference 3. This virus was
used to generate recombinant viruses with promoter substitutions in the
VP5 locus.
Generation of recombinant virus with the VP16, dUTPase, and
UL38 promoters controlling expression of the VP5
(UL19) transcript.
The VP5 transcription start site
occurs at base 40768 of the HSV strain 17syn+
(17). The BglII N fragment spanning bases 35734 through 41448 of the HSV-1 17syn+ genome,
containing the VP5 promoter and coding region, was freshly subcloned
from HSV 17syn+ DNA into the pGEM3 plasmid. An
XbaI linker was added to replace the HpaI site at
position
364 relative to the VP5 cap site. Digestion with
XbaI and AgeI yielded a fragment containing the
promoter from positions
364 to +268 in the VP5 translational reading
frame. This was subcloned into the Psp72 vector (Promega). Deletion of the VP5 TATA and the Inr elements was done by standard methods of
PCR-directed mutagenesis using appropriate primers. The mutated promoter, thus, contained a deletion from position
36 to position +20
relative to the cap site.
A DNA fragment containing the VP5 promoter sequence from position
364
to position
36 was generated by PCR using the upper-strand primer,
containing an XbaI linker and sequences from positions
364
to
348, and the downstream primer, containing a NotI
linker and sequences from positions
55 to
36. A second fragment,
containing the sequences from positions +20 to +268, was generated by
PCR using an upstream primer containing a ClaI linker with
sequences from positions +20 to +43 and a lower-strand primer
containing the AgeI restriction with sequences from
positions +290 to +322. The PCR products were digested with the
respective restriction enzymes and cloned into the Psp72 vector. The
sequences of the fragments were confirmed before the next ligation step.
The VP16 promoter containing sequences from positions

272 to +6, the
dUTPase promoter extending from

243 to +95, or the
U
L38
promoter with sequences from positions

97 to +87 was cloned
into
Bluescript KS(+) at the
XbaI and
HindIII
sites. The same
was done with a 300-bp bacterial chloramphenicol
acetyltransferase
(CAT) DNA "stuffer" fragment from
EcoRI- and
NcoI-digested plasmid
C15dv17 (
4,
5,
8). The Bluescript KS(+) vectors containing
the VP16, dUTPase,
U
L38, or the CAT stuffer were digested with
NotI
and
ClaI, and the resulting fragments were ligated along
with the VP5 fragments containing the promoter region to obtain
constructs with promoter insertions at the VP5 locus. These were
cloned
back into the
BglII N fragment, the sequences were checked
to ensure that no new mutation was introduced by PCR, and then
the
constructs were used to generate recombinant
viruses.
Generation of recombinant viruses.
The BglII N
plasmid constructs containing the substituted promoters were digested
with BglII to release the fragment and cotransfected with
infectious DNA isolated from the K5dZ virus (3, 27, 37) in
the C32 complementing cell line along with 8 µl of the Lipofectin
reagent (GIBCO-BRL). Recombinant viruses were isolated and screened on
C32 cells, using a 32P-labeled PvuI fragment
containing the VP5 coding region that was replaced by the
-galactosidase gene in the VP5-null virus (8, 19).
DNA from purified recombinant viruses was analyzed by PCR. This was
done by using an upper-strand oligonucleotide that binds
at positions

293 to

274 relative to the VP5 cap site (upstream
of the insertion
site) and an oligonucleotide that binds the lower
strand in the VP5
leader region at positions +67 to +117 (downstream
of the promoter
insertion site). The PCR products of the wt VP5
promoter, VP16/VP5,
dUTPase/VP5, and U
L38/VP5 and of the CAT stuffer
are 410, 688, 758, 594, and 710 bp, respectively. The PCR products
were
separated by agarose gel electrophoresis, and their identities
were
confirmed by Southern blotting with the
32P-labeled wt VP5,
VP16, dUTPase, U
L38, and CAT stuffer
probes.
Asymmetrically PCR-amplified DNA from all recombinant viruses was
directly sequenced by using the VP5 primer that binds in
the VP5 leader
region from positions +67 to +107 (
7,
10).
Independent
isolates were generated by separate transfections
to ensure that
promoter activity was not influenced by second-site
mutations.
RNA isolation and primer extension analysis.
RSF were
infected with recombinant viruses at a multiplicity of infection (MOI)
of 5 PFU per cell. Infections were allowed to proceed for 2, 4, 6, or
8 h, and total RNA was isolated by using Trizol reagent
(GIBCO-BRL) (11, 19). Primer extension analysis was carried
out with 10 µg of total RNA and 10 fmol of 32P-labeled
primers. A VP5 primer extending from 57 bases from the transcription
start site in the VP5 leader was used to detect the chimeric
transcripts. This primer gives rise to 63-, 142-, and 158-nucleotide
(nt) bands for the substituted VP16, dUTPase, and UL38
promoters, respectively. Primers specific for VP16 wt, dUTPase wt,
UL38 wt, and ICP27 transcripts were also used as internal controls. These produce products of 66, 143, 154, and 152 nt, respectively.
Multistep virus replication analysis.
RSF, Vero cells, and
mouse embryo fibroblasts (105 cells each) were seeded on
6-well plates. The next day, they were infected with 100 (for RSF and
Vero cells) or 10,000 (for mouse embryo fibroblasts) PFU per well.
After adsorption at 37°C for 1 h, viruses were decanted and
monolayers were overlaid with medium. Infectious viruses were harvested
at 12 to 72 h postinfection. Cells and the culture medium were
freeze-thawed three times, and virus titers were determined on Vero cells.
Primary HLF were allowed to become confluent, contact inhibited cells
in medium containing 15% FCS, or they were serum starved
for 7 days in
medium containing 0.25% FCS. These cells were then
infected with
various recombinant viruses, individually, at an
MOI of 0.05 PFU/cell.
Infectious viruses were harvested at 12
and 24 h postinfection,
and titers were determined on Vero cells
(
31).
Western blotting.
Individual RSF cultures (106
cells each) in 6-well plates were infected with virus at an MOI of 10 PFU/cell and harvested 24 h later. Proteins were separated on
sodium dodecyl sulfate-6% acrylamide gel electrophoresis and
electrophoretically transferred to nitrocellulose filters according to
procedures described elsewhere (15, 20, 30). The filters
were then blocked with 5% low-fat milk in phosphate-buffered saline
(PBS) for 1 h at room temperature. Then the filters were exposed
to antibody to the VP5 protein. This antibody (NC-1), kindly provided
by R. Eisenberg and G. Cohen, was used at a dilution of 1:10,000 in PBS
for 1 h at room temperature. After five washes in PBS, the filters
were incubated in PBS containing goat anti-rabbit immunoglobulin G and
VP5 protein was detected with an enhanced chemiluminescence detection
system (ECL; Amersham).
 |
RESULTS |
Deletion of the VP5 promoter from the viral genome.
A
schematic diagram outlining the replacement of the VP5 promoter is
shown in Fig. 1. To ensure that the only
modifications of the test virus were at the VP5 promoter, we generated
a novel clone of the 5.7-kb BglII N fragment from wt
17syn+ DNA. This fragment, spanning 0.23 to 0.27 µm,
extends 500 bp upstream of the VP5 transcript start site, through the
complete translational reading frame. As described in Materials and
Methods, we used PCR-directed mutagenesis to replace the VP5 TATA and
the initiator elements from positions
36 to +20 with NotI
and ClaI restriction sites. We then inserted the VP16
promoter (extending from positions
272 to +6), the dUTPase promoter
(extending from positions
243 to +95), or the UL38
promoter (extending from positions
97 to +87) in place of the deleted
VP5 TATA and initiator element in the VP5 locus.

View larger version (23K):
[in this window]
[in a new window]
|
FIG. 1.
Schematic representation of promoter substitutions in
the VP5 locus. The BglII fragment N freshly cloned from wt
HSV-1 (17syn+) was used to rescue the original
VP5-null virus to generate the VP5 rescue construct (VP5R). This was
used for all further constructions. The VP5 promoter and leader
sequences from positions 36 to +20, containing the TATA box and an
initiator element, were deleted and replaced with the VP16 ( 272 to
+6), dUTPase ( 243 to +95), or UL38 ( 97 to +87)
promoter. A 300-bp bacterial CAT DNA fragment stuffer was inserted as a
negative control. IRL, inverted long repeat;
IRS, inverted short repeat; TRL, terminal long
repeat.
|
|
Constructs were transfected along with infectious DNA from a VP5-null
virus on the C32 complementing cell line to generate
recombinant
viruses containing the various promoters at the VP5
locus. As a
positive control, the wt
BglII N fragment was used
to rescue
the VP5-null virus. Further, a 300-bp DNA fragment derived
from the
bacterial CAT gene was inserted in place of the VP5 promoter
as a
negative
control.
Recombinants were screened by hybridization and purified by three
rounds of plaque purification on complementing C32 cells
that express
the wt VP5 gene from its cognate promoter (
20).
DNA from
purified recombinant viruses was analyzed by PCR with
an upper-strand
oligonucleotide that binds at positions

293 to

274 relative to the
VP5 cap site (upstream of the insertion site)
and another
oligonucleotide that binds the lower strand in the
VP5 leader region at
positions +67 to +117 (downstream of the
promoter insertion site). The
PCR products of the wt VP5 promoter,
U
L38/VP5, dUTPase/VP5,
the CAT stuffer, and VP16/VP5, are 410,
594, 758, 710, and 688 bp in
size, respectively, and typical results
are shown on Fig.
2. To confirm their identities, the PCR
products
were separated by agarose gel electrophoresis and analyzed by
Southern blotting with the
32P-labeled wt VP5, VP16,
dUTPase, U
L38, or CAT stuffer probe (data
not shown).

View larger version (61K):
[in this window]
[in a new window]
|
FIG. 2.
DNA from purified recombinant viruses was analyzed by
PCR, using an upper-strand oligonucleotide that binds at positions
293 to 274 relative to the VP5 cap site (upstream of the insertion
site) and a second oligonucleotide that binds the lower strand in the
VP5 leader region at positions +67 to +117 (downstream of the promoter
insertion site). The PCR products of the wt VP5 promoter,
UL38/VP5, dUTPase/VP5, the CAT stuffer, and VP16/VP5, are
410, 594, 758, 710, and 688 bp, respectively. The PCR products were
separated by agarose gel electrophoresis. MWM, molecular size markers
(in base pairs).
|
|
Asymmetrically PCR-amplified DNA from all recombinant viruses was
directly sequenced by using the VP5 primer, which binds
in the VP5
leader region from positions +67 to +107 (
10). Independent
isolates were generated by separate transfections to ensure that
promoter activity was not influenced by second-site mutations
within
the inserted
region.
Analysis of the kinetics of the VP5 mRNA expressed under the
control of the VP16, dUTPase, or UL38 promoter.
Recombinant viruses were used to infect RSF, and total RNA was isolated
at various time points postinfection to assess the expression of VP5
mRNA under the control of the various promoters. The expression of wt
VP16, wt dUTPase, wt UL38, and ICP27 mRNA was also measured
as an internal control. Since the binding efficiency and the overall
sensitivity of each primer differs, we made no attempt to compare the
levels of various transcripts vis-à-vis each other. It is
noteworthy, however, that the relative levels of VP5 mRNA expressed
under the control of the various promoters generally reflected the
strength of those promoters as determined in quantitative assays
(36, 37).
VP5 mRNA was measured by primer extension, using a labeled probe
extending from base +67 of the VP5 leader region to detect
the
expression of the VP16/VP5, dUTPase/VP5, or U
L38/VP5
chimeric
transcripts. This primer gives rise to 63-, 142-, and 158-nt
bands
for the substituted VP16, dUTPase, and U
L38
promoters, respectively.
No additional start sites were found among all
of the recombinant
viruses
tested.
The VP5-rescued virus (VP5R) expressed the VP5 mRNA with the expected
leaky-late kinetics, equivalent to those of wt VP16
mRNA (Fig.
3). Similarly, the VP16/VP5 recombinant
virus expressed
chimeric VP5 mRNA with the same kinetics as it
expressed the wt
VP16 mRNA, which is essentially equivalent to that for
wt VP5
mRNA. It is evident that expression of the immediate-early ICP27
transcript, used as a control, was maximal at 4 h postinfection
and shut off after that

normal kinetics for this immediate-early
transcript. There was some variation in the ability to detect
appreciable ICP27 transcript at late times in repeated experiments,
but
the range of variability was the same for all recombinant
viruses
assayed. On the other hand, the VP5-null virus containing
the CAT
stuffer virus did not express any detectable VP5 transcript,
although
this virus expressed the VP16 transcripts with normal
kinetics. Thus,
the VP16 promoter can functionally substitute
for the inactive VP5
promoter.

View larger version (38K):
[in this window]
[in a new window]
|
FIG. 3.
Kinetics and levels of VP5 mRNA expression by the
VP5-rescued (VP5 R), VP16/VP5, and CAT/VP5 (CAAT/VP5) recombinant
viruses. RSF were infected with virus at an MOI of 5 PFU/cell, and
total RNA was isolated at various time points postinfection (P.I.).
Ten-microgram quantities of total RNA were analyzed by primer extension
with a primer extending from the VP5 leader region (+67), to detect the
chimera transcript, or with wt VP16 and ICP27 primers, used as internal
controls.
|
|
As shown on Fig.
4, the recombinant virus
containing the dUTPase/VP5 promoter expressed its VP5-encoding
transcripts with
early or

kinetics identical to that of the
internal wt dUTPase
transcript. This expression peaked at 4 h
postinfection and declined
thereafter. The
U
L38/VP5-containing recombinant virus expressed
its
VP5-encoding mRNA with late kinetics, with rates increasing
over time,
consistent with the expression of wt U
L38 transcript
(Fig.
4).

View larger version (38K):
[in this window]
[in a new window]
|
FIG. 4.
Kinetics and levels of chimeric VP5 mRNA expression by
the dUTPase/VP5 or UL38/VP5 recombinant virus. RSF were
infected with virus at an MOI of 5 PFU/cell, and total RNA was isolated
at various time points postinfection (P.I.). Ten-microgram quantities
of total RNA were analyzed by primer extension with a primer extending
from the VP5 leader region (+67), (to detect the chimera transcript) or
with wt dUTPase and wt UL38 primers (used as internal
controls).
|
|
Analysis of the VP5 chimera transcripts in the presence of a DNA
replication inhibitor.
The late kinetic class can be subdivided
into two subclasses: the leaky-late (
1) and the strict-late (
2).
Maximal expression of the late class requires viral DNA replication;
however, the
1 group is expressed at appreciable levels prior to the
initiation of viral DNA synthesis or in its absence. For this reason,
expression of proteins encoded by
1 transcripts is not particularly
sensitive to inhibitors of DNA replication. To confirm that expression
of the VP5 transcripts under the control of the UL38
promoter followed strict-late (
2) kinetics, recombinant viruses
containing the UL38/VP5 promoter were used to infect RSF in
the presence or absence of (400-µg/ml) phosphonoacetic acid (PAA).
Total mRNA was isolated at 2 and 8 h postinfection and subjected
to primer extension analyses as described above. Data are shown in Fig.
5. UL38 promoter-controlled VP5 transcription was markedly sensitive to the presence of PAA, as
evidenced by very low levels of mRNA at 8 h postinfection in the
presence of the drug. The same was observed with wt UL38
transcripts expressed in the same infection. On the other hand, the
expression of the VP16/VP5 chimera transcript was appreciably less
affected by PAA.

View larger version (32K):
[in this window]
[in a new window]
|
FIG. 5.
Primer extension analyses of total RNA from cells
infected with the UL38/VP5 and VP16/VP5 recombinant viruses
at 2 and 8 h postinfection in the presence (+) or absence ( ) of
PAA (400 µg/ml).
|
|
Expression of VP5 capsid protein following infection with
recombinant viruses.
We used Western blot analysis to determine
the amount of the VP5 capsid protein expressed in noncomplimenting
cells 24 h following infection with these recombinant viruses. As
shown in Fig. 6, the VP5R, VP16/VP5, and
dUTPase/VP5 viruses expressed high levels of VP5 protein upon infection
of Vero cells, while the UL38/VP5 virus expressed a
somewhat smaller amount of the VP5 capsid protein. In contrast, as
expected, essentially no VP5 protein was detected in cells infected
with either the VP5-null or CAT/VP5 virus.

View larger version (35K):
[in this window]
[in a new window]
|
FIG. 6.
Western blot analysis of major capsid protein expression
following infection with promoter-substituted viruses. RSF were
infected with virus at an MOI of 10 PFU/cell and harvested at 24 h
postinfection. Proteins were separated by SDS-6% polyacrylamide gel
electrophoresis and transferred to nitrocellulose filters. The filters
were probed for the expression of the VP5 capsid protein by using
antibody NC1, provided by R. Eisenberg and G. Cohen.
|
|
Growth analyses on noncomplementing cell lines.
Various
recombinant viruses were tested for growth on the complementing C32 and
noncomplementing Vero cell lines. As shown in Table
1, titers for the recombinant viruses
with the VP16, dUTPase, or the UL38 promoter controlling
VP5 mRNA expression were essentially equivalent on both cell lines,
Vero and C32. This was also the case with the VP5-rescued virus (VP5R).
On the other hand, the VP5-null virus containing the CAT stuffer
(CAT/VP5) failed to grow efficiently on Vero cells but grew to titers
equivalent to those attained by the rescued virus on the complementing
cell line.
To determine the efficiency of virus replication on some different cell
lines, viruses were infected at an MOI of 0.01 PFU/cell
on RSF and Vero
cells. A higher MOI of 1 PFU/cell was used with
the mouse embryo
fibroblasts. At 12, 24, 48, and 72 h postinfection,
yields of
infectious virus were measured by plaque assay. All
four recombinant
viruses expressing VP5 replicated equivalently
on these cells (Fig.
7). The CAT/VP5-null virus failed to
replicate
(data not shown).

View larger version (26K):
[in this window]
[in a new window]
|
FIG. 7.
Multiple-step growth of promoter-substituted viruses.
Virus was replicated in RSF, Vero cells, and mouse embryo fibroblasts
(MEF). RSF and Vero cells were infected at an MOI of 0.01 PFU/cell and
harvested at 12, 24, 48, and 72 h postinfection. Mouse embryo
fibroblasts were infected at an MOI of 1 PFU/cell and treated
equivalently. Infectious virus was quantified by plaque assay on Vero
cells.
|
|
To test for the ability of these recombinant viruses to replicate on
serum-starved or quiescent cells, primary HLF were grown
in medium with
0.25% FCS for 7 days or allowed to become quiescent
by maintaining
them under conditions of contact inhibition (
31).
Such cells
were then infected with the various recombinant viruses
at an MOI of
0.05 PFU/cell and incubated for 12 and 24 h. Infectious
virus was
freed from the infected-cell mass by three cycles of
freeze-thawing and
quantified by plaque assay. As shown in Table
2, all four viruses were able to
replicate efficiently in both
serum-starved and quiescent cells. The
VP5-null virus containing
the CAT stuffer did not replicate.
 |
DISCUSSION |
While the early-to-late switch in gene expression and its
correlation with gene function are hallmarks of DNA virus replication, the actual biological significance of altering the kinetics of expression of a given gene has not been widely studied in detail in
infections with animal viruses. In the present communication, we have
described an approach for investigating the biological manifestation
resulting from altering the kinetic "signature" of a specific viral
gene. We have used a VP5-null virus and a complementing cell line (C32)
to construct mutants of HSV-1 in which the expression of the major
capsid protein has been kinetically altered. In particular, we
generated an inactive VP5 promoter by deleting the TATA box and
initiator element (positions
36 to +20) and then inserted the strong
early (UL50 or dUTPase), the strict-late
(UL38), or a putatively equivalent leaky-late (VP16) promoter.
To ensure that there was no a priori selection for mutations that might
encourage virus replication in a deleterious background, infectious
DNAs from the VP5-null virus (K5dZ) and the modified BglII N
were cotransfected into the complementing cell line to generate
recombinant viruses. All subsequent rounds of virus purification were
also carried out in the absence of any selection such as might be found
by using a noncomplementing cell line for passage. The positive control
was VP5 rescued (VP5R), with its own promoter, and a 300-bp DNA
fragment derived from the bacterial CAT gene (CAT stuffer) was used in
the deleted region of the promoter as a negative control.
Analyses of the kinetics and levels of VP5 mRNA expression in
productively infected cells demonstrated that replacement of the TATA
box and initiator element with the CAT stuffer resulted in a completely
inactive promoter (Fig. 3). Promoter activity was restored by
substituting the VP16 (
) promoter. We will show elsewhere
(P. T. Lieu and E. K. Wagner, manuscript in preparation) that
there are significant differences in the detailed functional architecture of this promoter and that of the wt VP5 promoter. Here, it
suffices to observe that both the kinetics and levels of VP16/VP5
chimeric mRNAs were similar to those observed with VP5 mRNAs expressed
by rescued virus. Thus, despite the variations in promoter
architecture, promoters within the same kinetic class can readily
substitute for one another.
In contrast, and as expected, when an early or
kinetic class
promoter was inserted in the VP5 locus, the kinetics of the chimeric
VP5-encoding transcript followed the early kinetic class; i.e.,
activity peaked at 4 h postinfection and then declined. Furthermore, insertion of the strict-late UL38 promoter
resulted in the chimeric VP5-encoding mRNA accumulating with kinetics
identical to that of wt UL38 transcripts. The strict-late
kinetics of the VP5 transcript controlled by the UL38
promoter were confirmed by performing infections in the presence of a
DNA replication inhibitor, PAA. It is clear that the expression of the
chimeric VP5-encoding transcript was as sensitive to the action of PAA as was that of the wt UL38-encoding mRNA. This is in
contrast to the observation that the VP16 promoter-controlled
expression of VP5 mRNA was far less sensitive to PAA. These results are
fully consistent with our model holding that promoter architectures are, in large part, responsible for controlling the expression of
different classes of viral genes.
The expression of the VP5 capsid protein was detected by Western blot
analysis with a VP5 polyclonal antibody supplied by R. Eisenberg and G. Cohen, and some differences in the levels of protein expressed was
observed following infection with the various recombinant viruses. As
shown in Fig. 6, the amounts of the VP5 capsid protein expressed by the
VP16/VP5 and the dUTPase/VP5 viruses were essentially equivalent to
that expressed by the VP5-rescued virus. In contrast, reproducibly less
capsid protein was expressed in cells infected with the
UL38/VP5 virus. While the VP5 capsid protein was readily
detected by 4 h postinfection with the VP5R, dUTPase/VP5, and
VP16/VP5 viruses, the protein was not detected until 8 h after
infection with the UL38/VP5 virus (data not shown).
Despite these differences in the details of expression of the major
capsid protein, we found that there was no significant difference in
the efficiencies of replication of these various viruses in the
cultured cells tested. As shown in Table 1, the three recombinant
viruses expressing VP5 replicated to titers equivalent to that of the
rescued wt virus on both complementing (C32) and noncomplementing
(Vero) cells. The replication of the VP5-null virus containing the CAT
stuffer was reduced by more than 5 logs. Extremely low-level
replication of VP5-null virus on noncomplementing cells following its
isolation from complementing cells was also observed by Desai et al.
(3). This probably reflects a low level of recombination
between the VP5-null virus and the chromosome of the complementing cell
line. In addition, some virus growth may be a result of very limited
expression of the VP5 transcript from an upstream or inappropriate
promoter. Any such transcription was not detectable by primer extension.
Similarly, all VP5-expressing viruses replicated equivalently in
multistep growth experiments using RSF, Vero cells, and mouse embryo
fibroblasts. We also found that the VP5-expressing viruses all
replicated efficiently in primary HLF maintained under suboptimal conditions, such as serum starvation induced by prolonged incubation in
medium with 0.25% FCS or contact inhibition of growth.
These results, which were mildly surprising to us, suggest that
replication of HSV in cultured cells is relatively insensitive to the
exact kinetics of expression of the VP5 protein, at least under
conditions in which it can be expressed abundantly during some window
of time and accumulate. We have shown elsewhere that the dUTPase
promoter is a strong one (19). Indeed, as shown in Fig. 4,
the maximum amount of the VP5 transcript accumulating at its peak time
of expression is larger when controlled by the dUTPase promoter than
when controlled by either the VP16 or UL38 promoter.
Apparently, even though levels of the mRNA expressed early decline at
later times, there is sufficient capacity for the synthesis of the
capsid protein to attain maximum levels of virus production.
Alternatively, the stability of VP5 protein is sufficient to maintain
an adequate pool of protein late. This idea is supported by the fact
that the level of the VP5 capsid protein detected after 24 h
postinfection is equivalent in cells infected with either the
dUTPase/VP5, the VP16/VP5, or the rescued wt virus.
Our data also suggest that the putatively premature attainment of high
levels of VP5 capsid protein before the maximum synthesis of viral DNA
had no obvious deleterious effect on production of infectious virus.
Again, although the UL38/VP5 recombinant virus evidenced a
clearly lower level of accumulation of VP5 capsid protein by Western
blot analysis, this also had little or no effect on virus replication
in the cultured cells tested. These observations suggest that, not
surprisingly, the virus utilizes only a portion of the expressed capsid
protein for assembly. Taken together, our data provide evidence that
there is little stringency for the timing of appearance and levels of
the major capsid protein in the complex process of virion
morphogenesis, at least as measured by the formation of infectious virus.
While we have established that considerable latitude can be tolerated
in the timing of the appearance of high levels of the VP5 capsid
protein in the replication of HSV in cell culture, we do not think that
this will be reflected in the process of virus infection and spread in
the host. Analysis of the pathogenesis of these viruses in the animal,
where there is a requirement for virus replication in differentiated
cells, and tissues should reveal points and tissues for which the
timing of expression of this protein is critical. Further, we are
currently engaged in examining the effect of altering the kinetics of
expression of the less abundant UL38 protein on virus
replication. In this way, we expect to build a detailed analysis
concerning the specific role of the kinetics of expression of selected
viral genes in the replication process as a whole.
 |
ACKNOWLEDGMENTS |
M. Rice provided invaluable technical assistance. We thank P. Desai and S. Person for providing the cell line and VP5-null virus. We
also thank R. Eisenberg and G. Cohen for providing the NC1 antibodies.
G. B. Devi-Rao, M. Rice, S. Aguilar, and S. Stingly provided
useful input and critical reviews of the manuscript.
This work was supported in part by grant CA11861 from the National
Institutes of Health and by a predoctoral fellowship to P. T. Lieu
from a Gene Therapy for Cancer Training grant provided by the
University of California.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Program in
Animal Virology, Department of Molecular Biology and Biochemistry,
University of California, Irvine, CA 92697. Phone: (949) 824-5370. Fax:
(949) 824-8551. E-mail: ewagner{at}uci.edu.
 |
REFERENCES |
| 1.
|
Ace, C. I.,
T. A. McKee,
J. M. Ryan,
J. M. Cameron, and C. M. Preston.
1989.
Construction and characterization of a herpes simplex virus type 1 mutant unable to transinduce immediate-early gene expression.
J. Virol.
63:2260-2269[Abstract/Free Full Text].
|
| 2.
|
Blair, E. D., and B. W. Snowden.
1991.
Comparative analysis of the parameters that regulate expression from promoters of two late HSV-1 gene products, p. 181-206.
In
E. K. Wagner (ed.), Herpesvirus transcription and its regulation. CRC Press, Boca Raton, Fla.
|
| 3.
|
Desai, P.,
N. A. DeLuca,
J. C. Glorioso, and S. Person.
1993.
Mutations in herpes simplex virus type 1 genes encoding VP5 and VP23 abrogate capsid formation and cleavage of replicated DNA.
J. Virol.
67:1357-1364[Abstract/Free Full Text].
|
| 4.
|
Flanagan, W. M.,
A. G. Papavassiliou,
M. Rice,
L. B. Hecht,
S. Silverstein, and E. K. Wagner.
1991.
Analysis of the herpes simplex virus type 1 promoter controlling the expression of UL38, a true late gene involved in capsid assembly.
J. Virol.
65:769-786[Abstract/Free Full Text].
|
| 5.
|
Flanagan, W. M., and E. K. Wagner.
1987.
A bi-functional reporter plasmid for the simultaneous transient expression assay of two herpes simplex virus promoters.
Virus Genes
1:61-71[Medline].
|
| 6.
|
Godowski, P. J., and D. M. Knipe.
1986.
Transcriptional control of herpesvirus gene expression: gene functions required for positive and negative regulation.
Proc. Natl. Acad. Sci. USA
83:256-260[Abstract/Free Full Text].
|
| 7.
|
Guzowski, J. F.,
J. Singh, and E. K. Wagner.
1994.
Transcriptional activation of the herpes simplex virus type 1 UL38 promoter conferred by the cis-acting downstream activation sequence is mediated by a cellular transcription factor.
J. Virol.
68:7774-7789[Abstract/Free Full Text].
|
| 8.
|
Guzowski, J. F., and E. K. Wagner.
1993.
Mutational analysis of the herpes simplex virus type 1 strict late UL38 promoter/leader reveals two regions critical in transcriptional regulation.
J. Virol.
67:5098-5108[Abstract/Free Full Text].
|
| 9.
|
Homa, F. L.,
A. Krikos,
J. C. Glorioso, and M. Levine.
1991.
Functional analysis of regulatory regions controlling strict late HSV gene expression, p. 207-222.
In
E. K. Wagner (ed.), Herpesvirus transcription and its regulation. CRC Press, Boca Raton, Fla.
|
| 10.
|
Huang, C.-J.,
S. A. Goodart,
M. K. Rice,
J. F. Guzowski, and E. K. Wagner.
1993.
Mutational analysis of sequences downstream of the TATA box of the herpes simplex virus type 1 major capsid protein (VP5/UL19) promoter.
J. Virol.
67:5109-5116[Abstract/Free Full Text].
|
| 11.
|
Huang, C.-J., and E. K. Wagner.
1994.
The herpes simplex virus type 1 major capsid protein (VP5-UL19) promoter contains two cis-acting elements influencing late expression.
J. Virol.
68:5738-5747[Abstract/Free Full Text].
|
| 12.
|
Imbalzano, A. N., and N. A. DeLuca.
1992.
Substitution of a TATA box from a herpes simplex virus late gene in the viral thymidine kinase promoter alters ICP4 inducibility but not temporal expression.
J. Virol.
66:5453-5463[Abstract/Free Full Text].
|
| 13.
|
Jordan, R.,
L. Schang, and P. A. Schaffer.
1999.
Transactivation of herpes simplex virus type 1 immediate-early gene expression by virion-associated factors is blocked by an inhibitor of cyclin-dependent protein kinases.
J. Virol.
73:8843-8847[Abstract/Free Full Text].
|
| 14.
|
Junejo, F.,
A. R. MacLean, and S. M. Brown.
1991.
Sequence analysis of the herpes simplex virus type 1 strain 17 variants 1704, 1705, and 1706 with respect to their origin and effect on the latency-associated transcript sequence.
J. Gen. Virol.
72:2311-2315[Abstract/Free Full Text].
|
| 15.
|
Lamberti, C., and S. K. Weller.
1998.
The herpes simplex virus type 1 cleavage/packaging protein, UL32, is involved in efficient localization of capsids to replication compartments.
J. Virol.
72:2463-2473[Abstract/Free Full Text].
|
| 16.
|
Lieu, P. T.,
N. T. Pande,
M. K. Rice, and E. K. Wagner.
1999.
The exchange of cognate TATA boxes results in a corresponding change in the strength of two HSV-1 early promoters.
Virus Genes
20:5-10.
|
| 17.
|
McGeoch, D. J.
1991.
Correlation between HSV-1 DNA sequence and viral transcription maps, p. 29-48.
In
E. K. Wagner (ed.), Herpesvirus transcription and its regulation. CRC Press, Boca Raton, Fla.
|
| 18.
|
O'Hare, P.,
C. R. Goding, and A. Haigh.
1988.
Direct combinatorial interaction between a herpes simplex virus regulatory protein and a cellular octamer-binding factor mediates specific induction of virus immediate-early gene expression.
EMBO J.
7:4231-4238[Medline].
|
| 19.
|
Pande, N. T.
1997.
Functional analysis of two early gene promoters of herpes simplex virus type 1. Ph.D. dissertation.
University of California, Irvine.
|
| 20.
|
Person, S., and P. Desai.
1998.
Capsids are formed in a mutant virus blocked at the maturation site of the UL26 and UL26.5 open reading frames of herpes simplex virus type 1 but are not formed in a null mutant of UL38 (VP19C).
Virology
242:193-203[CrossRef][Medline].
|
| 21.
|
Roizman, B.
1999.
HSV gene functions: what have we learned that could be generally applicable to its near and distant cousins?
Acta Virol.
43:75-80[Medline].
|
| 22.
|
Roizman, B., and M. Tognon.
1983.
Restriction endonuclease patterns of herpes simplex virus DNA: application to diagnosis and molecular epidemiology.
Curr. Top. Microbiol. Immunol.
104:273-286[Medline].
|
| 23.
|
Sandri-Goldin, R. M.,
A. L. Goldin,
L. E. Holland,
J. C. Glorioso, and M. Levine.
1983.
Expression of herpes simplex virus and genes integrated in mammalian cells and their induction by an gene product.
Mol. Cell. Biol.
3:2028-2044[Abstract/Free Full Text].
|
| 24.
|
Sears, A. E., and B. Roizman.
1990.
Amplification by host cell factors of a sequence contained within the herpes simplex virus 1 genome.
Proc. Natl. Acad. Sci. USA
87:9441-9444[Abstract/Free Full Text].
|
| 25.
|
Shaw, P.,
J. Knez, and J. P. Capone.
1995.
Amino acid substitution in the herpes simplex virus transactivator VP16 uncouple direct protein-protein interaction and DNA binding from complex assembly and transactivation.
J. Biol. Chem.
270:29030-29037[Abstract/Free Full Text].
|
| 26.
|
Silver, S., and B. Roizman.
1985.
2-Thymidine kinase chimeras are identically transcribed but regulated as 2 genes in herpes simplex virus genomes and as genes in cell genomes.
Mol. Cell. Biol.
5:518-528[Abstract/Free Full Text].
|
| 27.
|
Singh, J., and E. K. Wagner.
1995.
Herpes simplex virus recombination vectors designed to allow insertion of modified promoters into transcriptionally "neutral" segments of the viral genome.
Virus Genes
10:127-136[CrossRef][Medline].
|
| 28.
|
Steffy, K. R., and J. P. Weir.
1991.
Mutational analysis of two herpes simplex virus type 1 late promoters.
J. Virol.
65:6454-6460[Abstract/Free Full Text].
|
| 29.
|
Takasu, T.,
Y. Furuta,
K. C. Sato,
S. Fukuda,
Y. Inuyama, and K. Nagashima.
1992.
Detection of latent herpes simplex virus DNA and RNA in human geniculate ganglia by the polymerase chain reaction.
Acta Oto-Laryngol.
112:1004-1011[Medline].
|
| 30.
|
Thomsen, D. R.,
W. W. Newcomb,
J. C. Brown, and F. L. Homa.
1995.
Assembly of the herpes simplex virus capsid: requirement for the carboxyl-terminal twenty-five amino acids of the proteins encoded by the UL26 and UL26.5 genes.
J. Virol.
69:3690-3703[Abstract].
|
| 31.
|
Van Sant, C.,
Y. Kawaguchi, and B. Roizman.
1999.
A single amino acid substitution in the cyclin D binding domain of the infected cell protein no. 0 abrogates the neuroinvasiveness of herpes simplex virus without affecting its ability to replicate.
Proc. Natl. Acad. Sci. USA
96:8184-8189[Abstract/Free Full Text].
|
| 32.
|
Wagner, E. K.
1983.
Transcription patterns in herpes simplex virus infections, p. 239-270.
In
G. Klein (ed.), Advances in viral oncology, vol. III. Raven Press, New York, N.Y.
|
| 33.
|
Wagner, E. K.
1999.
Herpes simplex virus molecular biology, p. 686-697.
In
R. G. Webster, and A. Granoff (ed.), Encyclopedia of virology. Academic Press, London, United Kingdom.
|
| 34.
|
Wagner, E. K.,
K. P. Anderson,
R. H. Costa,
G. B. Devi-Rao,
B. Gaylord,
L. E. Holland,
J. R. Stringer, and L. Tribble.
1981.
Isolation and characterization of HSV-1 mRNA, p. 45-68.
In
Y. Becker (ed.), Herpesvirus DNA: recent studies on the internal organization and replication of the viral genome. Martinus Nijhoff B.V., The Hague, The Netherlands.
|
| 35.
|
Wagner, E. K.,
R. H. Costa,
G. B. Devi-Rao,
K. Draper,
R. J. Frink,
L. Hall,
M. Rice, and W. Steinhart.
1985.
Herpesvirus mRNA, p. 79-100.
In
Y. Becker (ed.), Developments in molecular virology, vol. VI. Martinus Nijhoff, The Hague, The Netherlands.
|
| 36.
|
Wagner, E. K.,
J. F. Guzowski, and J. Singh.
1995.
Transcription of the herpes simplex virus genome during productive and latent infection, p. 123-168.
In
W. E. Cohen, and K. Moldave (ed.), Progress in nucleic acid research and molecular biology. Academic Press, San Diego, Calif.
|
| 37.
|
Wagner, E. K.,
M. D. Petroski,
N. T. Pande,
P. T. Lieu, and M. K. Rice.
1998.
Analysis of factors influencing the kinetics of herpes simplex virus transcript expression utilizing recombinant virus.
Methods
16:105-116[CrossRef][Medline].
|
| 38.
|
Weinheimer, S. P., and S. L. McKnight.
1987.
Transcriptional and post-transcriptional controls establish the cascade of herpes simplex virus protein synthesis.
J. Mol. Biol.
195:819-833[CrossRef][Medline].
|
Journal of Virology, March 2000, p. 2770-2776, Vol. 74, No. 6
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Sun, A., Devi-Rao, G. V., Rice, M. K., Gary, L. W., Bloom, D. C., Sandri-Goldin, R. M., Ghazal, P., Wagner, E. K.
(2004). Immediate-Early Expression of the Herpes Simplex Virus Type 1 ICP27 Transcript Is Not Critical for Efficient Replication In Vitro or In Vivo. J. Virol.
78: 10470-10478
[Abstract]
[Full Text]
-
Tran, R. K., Lieu, P. T., Aguilar, S., Wagner, E. K., Bloom, D. C.
(2002). Altering the Expression Kinetics of VP5 Results in Altered Virulence and Pathogenesis of Herpes Simplex Virus Type 1 in Mice. J. Virol.
76: 2199-2205
[Abstract]
[Full Text]
-
Stingley, S. W., Ramirez, J. J. G., Aguilar, S. A., Simmen, K., Sandri-Goldin, R. M., Ghazal, P., Wagner, E. K.
(2000). Global Analysis of Herpes Simplex Virus Type 1 Transcription Using an Oligonucleotide-Based DNA Microarray. J. Virol.
74: 9916-9927
[Abstract]
[Full Text]